Recursion, a biopharma company, uses a data-driven approach to drug discovery, launching four clinical trials and planning a fifth in oncology. Recursion's software platform, the Recursion OS, is used ...
Recursion's share price continues to be volatile, despite its pipeline maturing and the injection of significant cash through its merger with Exscientia. While early clinical data has been marginal, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results